Prevalence, beliefs and impact of drug-drug interactions between antiretroviral therapy and illicit drugs among people living with HIV in Spain
Castro-Granell, V. (Hospital Marina Baixa (La Vila Joiosa, Alacant))
Garin, Noe (Institut d'Investigació Biomèdica Sant Pau)
Jaén, Ángeles (Fundació Docència i Recerca Mútua Terrassa)
Cenoz, Santiago (ViiV Healthcare (Tres Cantos, Madrid))
Galindo, María José (Hospital Clínic Universitari (València))
Fuster-RuizdeApodaca, María José (Sociedad Española Interdisciplinaria del Sida)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Drug use implies important challenges related to HIV management, particularly due to an increased risk of potential interactions between antiretroviral therapy (ART) and illicit drugs (pDDIs). This study analyses the prevalence and severity of pDDIs among people living with HIV (PLHIV). It also explores their awareness of pDDIs and their beliefs about the toxicity that they may cause, as well as the impact of pDDIs on selected health variables. We conducted an on-line cross-sectional survey across 33 Spanish hospitals and NGOs to collect demographics and clinical data. pDDIs were checked against the Interaction Checker developed by Liverpool University. The sample of the present study was composed of 694 PLHIV who used illicit drugs. They represented 49. 5% of the 1,401 PLHIV that participated in the survey. After excluding 38 participants due to lack of information on their ART or illicit drug use, 335 (51. 1%) participants consuming drugs presented with some potentially significant pDDIs between their ART and illicit drugs, with a mean of 2. 1±1. 7 (1-10) pDDIs per patient. The drugs most frequently involved in pDDIs were cocaine, cannabis, MDMA and nitrates ("poppers"). The prevalence of pDDIs across ART regimens was: protease inhibitors (41. 7%); integrase inhibitor-boosted regimens (32. 1%), and non-nucleoside reverse transcriptase inhibitors (26. 3%). An awareness of pDDIs and beliefs about their potential toxicity correlated positively with intentional non-adherence (p<0. 0001). Participants with pDDIs exhibited a higher prevalence of intentional non-adherence (2. 19±1. 04 vs. 1. 93±0. 94; p = 0. 001). The presence of pDDIs was not associated with poorer results in the clinical variables analysed. A significant proportion of PLHIV who use drugs experience pDDIs, thereby requiring close monitoring. pDDIs should be considered in the clinical management of HIV patients. Adequate information about pDDIs and indicators about how to manage ART when PLHIV use drugs could improve ART non-adherence.
Nota:	Altres ajuts: ViiV Healthcare (grant 001/2016)
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adult ; Antiretroviral Therapy, Highly Active ; Cross-Sectional Studies ; Drug Interactions ; Female ; HIV Infections ; HIV Integrase Inhibitors ; Hospitals ; Humans ; Illicit Drugs ; Male ; Prevalence ; Protease Inhibitors ; Reverse Transcriptase Inhibitors ; Spain
Publicat a:	PloS one, Vol. 16 Núm. 11 (november 2021) , p. e0260334, ISSN 1932-6203

DOI: 10.1371/journal.pone.0260334
PMID: 34797882

19 p, 1.7 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats